NCT07232732

A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.

Conditions

• Healthy
• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	LY3549492	Administered orally

Timeline

• Start date: 2025-10-27
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2025-11-18
• Last updated: 2026-03-05

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study